INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference
INmune Bio Inc. - Common stock (INMB)
Company Research
Source: GlobeNewswire
Boca Raton, FL, Nov. 18, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces two presentations at the upcoming 18th Clinical Trials on Alzheimer’s Disease conference (CTAD), in San Diego, CA on December 1-4, 2025. Presentations: Title:XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer’s Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial Date:Monday, December 1, until Tuesday December 2, 2025 Time:3:30pm (December 1st) – 5:30pm (December 2nd) PT Location:P057 Presenting author:Kim A. Staats, PhD. INmune Bio. Title:Validation of the Early Mild Alzheimer’s Cognitive Composite (EMACC) Through Associations with Blood-Based Biomarkers of Alzheimer’s Disease Date:Thursday, December 4, 2025 Time:7:15am - 5:00pm PT Location:P316
Show less
Read more
Impact Snapshot
Event Time:
INMB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INMB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INMB alerts
High impacting INmune Bio Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
INMB
News
- Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ PlatformGlobeNewswire
- INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595's Evidence Base in High-Inflammation Alzheimer's Patients [Yahoo! Finance]Yahoo! Finance
- INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer's PatientsGlobeNewswire
- INmune Bio (NASDAQ:INMB) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=INMB&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a>MarketBeat
- INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
INMB
Earnings
- 10/30/25 - Beat
INMB
Sec Filings
- 12/3/25 - Form 8-K
- 12/2/25 - Form 4
- 12/2/25 - Form 4
- INMB's page on the SEC website